Document:

Amendment to License Agreement

 Exhibit 10.32 
 NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been
redacted and are marked with a “[***]” in the place of the redacted language. The redacted information has been filed separately with the Commission. 
 AMENDMENT TO LICENSE AGREEMENT 
 THIS AMENDMENT TO LICENSE AGREEMENT
(the “Amendment”) is made and entered into effective as of April 29, 2008 (the “Amendment Effective Date”), by and between The Scripps Research Institute, a California nonprofit public benefit corporation
(“Scripps”), and Sangamo BioSciences, Inc., a Delaware corporation (“Licensee”), having principal offices at 501 Canal Blvd., Suite A100, Richmond, CA 94804. 
 Scripps and Licensee hereby agree to amend that certain License Agreement, dated March 14, 2000 (the “Agreement”) as follows:

 1. Definitions. All defined terms used and not otherwise defined in this Amendment have the meanings ascribed to such terms in
the Agreement. The following terms, when capitalized, have the following meanings and shall be added to Section 1 of this Agreement: 
 (a) “Expressed Protein” means a recombinant protein expressed by a Modified Cell Line. 
 (b) “Genentech” means Genentech, Inc. 
 (c)
“Genentech Agreements” mean that certain Research and License Agreement between Genentech and Licensee, dated April 27, 2007, and that certain Second Research and License Agreement between Genentech and Licensee, dated
February 25, 2008, in each case as amended as of the Amendment Effective Date, but prior to any amendments subsequent to the Amendment Effective Date. 
 (d) “Genentech Revenue” means any cash compensation (including, without limitation, any fees, milestone payments, or running royalties (if any)) received by Licensee from Genentech
under either of the Genentech Agreements. 
 (e) “Modified Cell Line” has the meaning assigned to it in
the Genentech Agreements. 
 (f) “Primary Genentech Revenue” means Genentech Revenue for which no Sigma
Payments are owed. 
 (g) “Secondary Genentech Revenue” means Genentech Revenue (other than Primary
Genentech Revenue), less any Sigma Payments applicable thereto. 
 (h) “Sigma” means Sigma-Aldrich Co.

 (i) “Sigma Payment” means any portion of Genentech Revenue that Licensee is obligated to remit to
Sigma pursuant to a written agreement with Sigma. 

 (j) “Special Product” means any product incorporating an Expressed
Protein (provided such product does not incorporate any Licensed Product that is not an Expressed Protein) 
 (k)
“Sublicensee” means any third party (including Affiliates) to which Licensee grants a sublicense under the Scripps Technology and/or the Scripps Patent Rights. 
 2. The following shall be added as a new Section 2.7.1 of the Agreement: 
 “2.7.1. Royalties on Genentech Revenue. Licensee shall pay royalties on Primary Genentech Revenue and Secondary Genentech Revenue at the following royalty rates: 
  

			
	 (a) Primary Genentech
Revenue
	  	[***]%
	 (b) Secondary Genentech Revenue
	  	[***]%
 (subject to the
following
paragraph)

 Notwithstanding the foregoing, in the event that, pursuant to a license under patents owned or controlled by parties other than Scripps, Licensee must pay the applicable licensor(s) a portion of any
Secondary Genentech Revenue, Licensee may deduct from the royalties payable under Section 2.7.1(b) an amount equal to [***] percent ([***]%) of such portion of Secondary Genentech Revenue payable to such licensor(s).
Notwithstanding the foregoing, the amount payable to Scripps under Section 2.7.1(b) shall in no event be less than [***] percent ([***]%) of the Secondary Genentech Revenue. 
 Payments under this Section 2.7.1 shall be due sixty (60) days after Licensee receives the applicable Primary Genentech Revenue or Secondary
Genentech Revenue.” 
 3. The following shall be added at the end of Section 2.3.1 of the Agreement: 
 “Scripps acknowledges and agrees that (i) no royalties shall be owed to Scripps under this Section 2.3.1 of the Agreement on
sales of any Special Product by Genentech or its affiliates or licensees; (ii) no royalties shall be owed to Scripps under this Section 2.3.1 of the Agreement with respect to any Genentech Revenue; and (iii) no payments will be owed
to Scripps under this Agreement with respect to any portion of Genentech Revenue that is remitted to Sigma as a Sigma Payment.” 
 4. As of the Amendment Effective Date, all references in Section 2.3.2 to $[***] shall be changed to $[***]. 
 5. The following shall be added as a new Section 2.7.2 of the Agreement: 
 “Scripps acknowledges and
agrees that the right to sublicense granted in Section 2.1 of this Agreement includes the right to sublicense to various sublicensees in different

  

 *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
subfields of use within the Field (and in the case of nonexclusive sublicenses, overlapping subfields of use within the Field). However, none of Licensee’s sublicensees shall have the right
to further sublicense without Scripps’ prior written consent. Scripps’ right to approve sublicenses is solely to ensure that such sublicense agreements comply with the provisions of this Section 2.7. Licensee must provide Scripps with
a copy of each sublicense agreement within thirty (30) days of its effective date.” 
 6. The following language is hereby
added as a new Section 8.7, which shall survive any termination of the Agreement: 
 “8.7. Survival of
Sublicenses. Any sublicense shall, at the election of the applicable Sublicensee, survive termination of this Agreement, in accordance with the provisions of this Section 8.7. Upon termination of this Agreement, Scripps hereby grants to
each Sublicensee, not then in default, an option to obtain directly from Scripps a license agreement on the terms set forth below, which option shall be exercisable by such Sublicensee during the sixty (60) day period commencing on the later of
the date of termination of this Agreement pursuant to this Section 8 or when such Sublicensee learns of such termination. In the event a Sublicensee elects to exercise this option and provides its written notice thereof within the sixty
(60) day period, as a condition precedent to Scripps’ obligation to grant the direct license to that Sublicensee, such Sublicensee (or if there is at such time more than one Sublicensee exercising this option, then those Sublicensees
jointly and severally) must pay to Scripps all past due royalties, non-royalty revenue, patent costs and all other monies owed by Licensee to Scripps under this Agreement (the “Past Due Amount”). Upon request of any Sublicensee,
Scripps shall disclose to such Sublicensee (in confidence) the Past Due Amount, and Licensee hereby waives any confidentiality or other rights with respect to such information, solely to the extent necessary for Scripps to provide such information
to such Sublicensee in accordance with this Section 8.7. In addition, Scripps shall use reasonable efforts to facilitate communication between Sublicensees that indicate a desire to coordinate a joint payment of the Past Due Amount. Upon
Scripps’ receipt of the Past Due Amount, Scripps shall enter into a license agreement (a “New License Agreement”) directly with each requesting Sublicensee and the license granted in each New License Agreement shall be
retroactive to the date of termination of this Agreement. Each New License Agreement shall be subject to the same non-financial terms and conditions as those in this Agreement; provided, however, that each New License Agreement shall contain
substantially the same terms and conditions regarding sublicense scope, sublicense territory, duration of sublicense grant, and diligence obligations as the sublicense agreement between such Sublicensee and Licensee. In addition, (i) each
Sublicensee shall agree in the New License Agreement to terms providing that in no event shall Scripps be liable to Sublicensee for any actual or alleged breach of such sublicense agreement by Licensee; (ii) Scripps shall not have any
obligations to such Sublicensee other than Scripps’ obligations to Licensee as set forth herein; and (iii) in no event shall Scripps be obliged to accept provisions in the New License Agreement (a) unless such provisions correspond to
rights granted by Licensee to Sublicensee in conformance with this Agreement and such provisions are not in conflict with the rights, duties and obligations accruing to the Licensee under this Agreement; or (b) where such provisions are
inconsistent with the legal obligations under any other sublicense agreement granted

 
by Licensee, or by applicable federal, state or local statute or regulation. The financial consideration to Scripps under the New License Agreement shall be as follows: (A) such Sublicensee
(or if there is at such time more than one such Sublicensee who elects to enter into a New License Agreement, such Sublicensees jointly and severally) shall be required to make any minimum annual royalties due pursuant to Section 2.3.2 and to
pay Licensee’s share of any patent costs, as set forth in Section 3.2; and (B) each such Sublicensee shall be required to make any monetary payment(s) that, had this Agreement not been terminated, Licensee would have been required to
make under this Agreement as a result of the activities of such Sublicensee. Notwithstanding the foregoing, in no event shall the minimum annual royalties due pursuant to Section 2.3.2 by a particular Sublicensee for any twelve (12) month
period specified therein (i.e., any calendar year) exceed the greater of [***] Dollars ($[***]) or [***] percent ([***]%) of the total royalties payable under the New License Agreement by such Sublicensee (if any) during
the immediately preceding twelve (12) month period. Each Sublicensee shall be an intended third party beneficiary of this Section 8.7, to the extent such Sublicensee exercises its option under this Section 8.7. Licensee must include
or specifically reference this Section 8.7 in each of its sublicense agreements in order for such Sublicensee to have the option described above.” 
 7. Representations. Licensee hereby represents and warrants to Scripps that (a) none of the payments owed by Genentech under that certain Research and License Agreement between
Genentech and Licensee, dated April 27, 2007, is a Sigma Payment; (b) as of the Amendment Effective Date, Licensee does not anticipate that the Modified Cell Lines and Special Products contemplated by the Genentech Agreements will be
covered by the claims of the Scripps Patent Rights; and (c) Licensee has not granted to Genentech any licenses under the Scripps Patent Rights to sell, offer for sale, or have sold Modified Cell Lines or Special Products. 
 8. Miscellaneous. This Amendment amends the terms of the Agreement as expressly provided above, and the Agreement, as so amended and including
all of its other terms and provisions that are not amended, remains in full force and effect. 
 IN WITNESS WHEREOF, the
parties hereto have caused this Amendment to License Agreement to be executed by their duly authorized representatives as of the Amendment Effective Date. 
  

			
	THE SCRIPPS RESEARCH INSTITUTE
		
	By:	 	 /s/ Polly A. Murphy

		
	Name:	 	 Polly A. Murphy, DVM, Ph.D

		
	Title:	 	 Senior Vice President
 Business and Scientific Services

  

 *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

			
	SANGAMO BIOSCIENCES, INC.
		
	By:	 	 /s/ David G. Ichikawa

		
	Name:	 	 David G. Ichikawa

		
	Title:	 	 SVP Business DevelopmentSecond Amendment of Research and Commercial Option License Agreement

 Exhibit 10.39 
 NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been
redacted and are marked with a “[***]” in the place of the redacted language. The redacted information has been filed separately with the Commission. 
 SECOND AMENDMENT OF THE RESEARCH AND COMMERCIAL LICENSE OPTION AGREEMENT 
 The Parties to
the Research and Commercial License Option Agreement of October 1, 2005 as previously amended (“Agreement”), Sangamo BioSciences, Inc., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501
Canal Boulevard, Suite A100, Richmond, California 94804 (“Sangamo”), and Dow AgroSciences LLC, a Delaware limited liability company having its principal place of business at 9330 Zionsville Road, Indianapolis, IN 46268 (“DAS”),
hereby further amend the Agreement as follows: 
 A. Sangamo acknowledges that it has received all payments due from DAS pursuant to
Section 8.3(a) of the Agreement for the Research Program through the end of the Initial Research Term which expired on September 31, 2008, and each Party acknowledges that payment by DAS of a final five hundred thousand dollar ($500,000)
payment, that will be invoiced by Sangamo as of January 31, 2008, will satisfy DAS’s research funding obligations for the Research Program through the end of 2008. 
 B. Section 8.3 (b) of the Agreement is amended to read: 
 “(b) DAS and Sangamo
agree to carry out, subject part “D” of the Second Amendment to this Agreement, the following Research Plan during calendar year 2009 of the Subsequent Research Term, which Research Plan has the four following elements with the indicated
budget for each element: 
 Element 1. $162,500 for [***] FTE at Sangamo to endeavor to establish a [***]
sequence-based methodology for analysis of genome editing and to transfer such methodology to DAS as it is being developed. 
 Element 2. $487,500 for [***] FTEs at Sangamo to endeavor to identify and characterize [***] domains for use as zinc-finger protein fusion partners, including research directed to developing a [***] system for
testing potential [***] of zinc-finger proteins and, in collaboration with DAS, establishing a [***] system for testing potential [***] of zinc-finger proteins. 
 Element 3. $1,625,000 for [***] FTEs at Sangamo to support the following ZFP/ZFN supply activities: 
 a. Supplying (including design, assembly, and optimization as necessary) DAS with ZFP Products for up to [***] targets, but not more
than [***] targets per quarter and [***] targets per month; provided, however, that if Sangamo is not

  

 *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
able to generate ZFP Products for a particular target despite good faith attempts to do so, Sangamo may discontinue work on such target after discussing such matter with DAS. 
 b. Providing [***] DNA (ZFN) and [***] (ZFP TF) Assays. 
 c. Providing molecular biology support such as cloning into DAS vectors and running [***] assays, [***] assays and genomic
[***] and [***] detection assays. 
 The Parties agree that DAS may request that Sangamo supply ZFP Products for more than
[***] targets in 2009 and, if Sangamo accepts any such requests for supplying ZFP Products for additional targets, then Sangamo will provide such supply-related services at $[***] per additional target. 
 Element 4. $487,500 for [***] FTEs to perform the following technology transfer activities at Sangamo during the first six
months of 2009: 
 a. Sangamo to consult with DAS and Sigma-Aldrich Co. (“Sigma”) and transfer during
the first quarter of 2009 (“Q1”) and the second quarter of 2009 (“Q2”) as much of DAS’s third quarter of 2009 (“Q3”) and fourth quarter of 2009 (“Q4”) ZFP Product [***] to Sigma as DAS decides is
practicable. 
 b. Sangamo effort during Q1 and Q2 to expand archive to [***] members 
 c. Sangamo effort during Q1 to streamline the [***] process 
 d. Sangamo effort during Q1 to transfer [***] assay system to Sigma 
 e. Sangamo effort during Q2 to transfer [***] archive to Sigma 
 f. Sangamo effort during Q2 to transfer [***] technology to Sigma. 
 If the technology transfer to Sigma is not completed by June 30, 2009, the Parties will mutually agree upon the FTEs required and deliverables and
payment schedule for the additional technology transfer that is required.” 
 C. DAS shall pay the following amounts to Sangamo for its
Diligent Efforts to perform the Research Plan described in part “B” above: 
  

	 	a.	$812,500 per quarter for each of Q1 and Q2 (billed net 30 days at the beginning of each quarter (or in the case of Q1, as soon as practicable after the signing of this
Second Amendment)); 

  

	 	b.	$568,750 for each of Q3 and Q4 (billed net 30 days at the beginning of each quarter); 

  

	 	c.	Additional amounts for more than 25 targets to be paid net 30 days from the date the request is accepted by Sangamo; 

  

	 	d.	Additional amounts for tech transfer or other services requested by DAS and accepted by Sangamo will be billed monthly and paid net 30 days. 

 

	 	e.	A mutually agreed upon amount for any [***] performed by Sangamo on behalf of DAS and will be billed monthly and paid net 30 days. 

 D. DAS may cancel any part of the work to be carried out after June 30, 2009, on ninety (90) days written notice. The work scheduled to be carried
out prior to June 30,

  

 *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 

 
2009 may only be cancelled as result of termination of the Agreement in accordance with Section 11.6 of the Agreement on account of the uncured material breach of a Party. 
 E. Except as amended hereby or pursuant to the First Amendment, the Agreement shall remain in full force and effect. Those amendments made herein shall be
effective as of the Second Amendment Effective Date. 
 IN WITNESS
WHEREOF, the Parties have executed this Second Amendment of the Research and Commercial License Option Agreement in duplicate originals by their proper officers as of January
            , 2009 (“Second Amendment Effective Date”). 
 AGREED TO AND
ACCEPTED BY: 
  

									
	Sangamo BioSciences, Inc.	 		 	Dow AgroSciences LLC
					
	By:	 	 /s/ Philip Gregory
	 		 	By:	 	 /s/ William A. Kleschick

		 	Philip Gregory, D.Phil.	 		 		 	William A. Kleschick, Ph.D.
	Title:	 	Vice President, Research	 		 	Title:	 	Global Leader, Discovery
					
	Date:	 	 January 28, 2009
	 		 	Date:	 	 February 10, 2009

					
		 		 		 	By:	 	 /s/ Jerome Peribere

		 		 		 		 	Jerome Peribere
					
		 		 		 	Title:	 	President & CEO
					
		 		 		 	Date:	 	 February 13, 2009

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]